share_log

藥明巨諾-B:第九次經修訂及重述的組織章程大綱及細則

JW THERAP-B: NINTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION

HKEX ·  Jun 18, 2024 17:02

Summary by Moomoo AI

藥明巨諾-B於2024年6月18日通過特別決議案,完成了對公司組織章程大綱及細則的第九次修訂及重述。該修訂涉及公司名稱、註冊辦事處位置、公司設立目標、股東責任、股本結構、公司註冊及撤銷等多項內容。此外,修訂細則還包括了股份轉讓、股東大會程序、董事會運作、秘書職務、印章使用、賬目與審計、股息分派政策等方面的具體規定。這次修訂旨在使公司組織章程更加完善,以符合當前運營需求和法律法規的要求。
藥明巨諾-B於2024年6月18日通過特別決議案,完成了對公司組織章程大綱及細則的第九次修訂及重述。該修訂涉及公司名稱、註冊辦事處位置、公司設立目標、股東責任、股本結構、公司註冊及撤銷等多項內容。此外,修訂細則還包括了股份轉讓、股東大會程序、董事會運作、秘書職務、印章使用、賬目與審計、股息分派政策等方面的具體規定。這次修訂旨在使公司組織章程更加完善,以符合當前運營需求和法律法規的要求。
On June 18, 2024, WuXi Biologics completed its ninth revision and restatement of its articles of incorporation and bylaws through a special resolution. The revision involves many aspects of the company, including company name, registered office address, company objectives, shareholders' responsibilities, share capital structure, company registration and cancellation, etc. In addition, the revised bylaws also include specific provisions on share transfers, shareholder meetings procedures, board of directors' operations, secretary duties, seal use, accounting and auditing, dividend distribution policies, and other aspects. This revision aims to make the company's articles of incorporation more perfect to meet the current operation requirements and legal requirements.
On June 18, 2024, WuXi Biologics completed its ninth revision and restatement of its articles of incorporation and bylaws through a special resolution. The revision involves many aspects of the company, including company name, registered office address, company objectives, shareholders' responsibilities, share capital structure, company registration and cancellation, etc. In addition, the revised bylaws also include specific provisions on share transfers, shareholder meetings procedures, board of directors' operations, secretary duties, seal use, accounting and auditing, dividend distribution policies, and other aspects. This revision aims to make the company's articles of incorporation more perfect to meet the current operation requirements and legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more